Briefing
Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
utDNA-positive rate fell from 85% at baseline to 55% pre-cystectomy. Clearance was associated with longer EFS (HR 0.24, 95% CI 0.09-0.62) and was 12 percentage points higher with durvalumab (39% vs 27%). Pre-cystectomy utDNA-negative status was associated with pCR (72% [55/76] vs 18% [17/96] if utDNA-positive). Estimated 24-month EFS was 90% if dual-negative, 75% if utDNA-positive only, and 55% if dual-positive.
- n: 265 biomarker-evaluable (25% of 1063 randomized)
- Assay: Signatera for ctDNA (named in the related NIAGARA ASCO 2025 abstract). utDNA as described in this abstract.